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1. Abstract  
Objectives 
To determine the effectiveness of long-term lifestyle interventions for the prevention of weight gain and morbidity 
in adults.   
Methods 
Prevention of weight gain is important in adults who are normal weight, overweight and obese. A systematic 
review of controlled trials of lifestyle interventions in adults with a body mass index of less than 35kg /m
2 with at 
least two years follow-up was carried out.  
Results  
Eleven of 39 comparisons produced significant improvement in weight between groups at two years or longer with  
mean difference weight change ranging from -0.5 kg to 11.5 kg. Effective interventions included a 600kcal/day 
deficit/low-fat diet (with and without meal-replacements), low-calorie diet, Weight-Watchers diet, low-fat non-
reducing diet, diet with behaviour therapy, diet with exercise, diet with exercise and behaviour therapy. Adding 
meal replacements to a low-fat diet (with and without exercise and behaviour therapy) produced significant 
improvement in weight. Head-to-head interventions failed to show significant effect on weight with the exception 
of a Mediterranean diet with behaviour therapy compared to low-fat diet. Diet with exercise and/or behaviour 
therapy demonstrated significant reduction in hypertension and improvement in risk of metabolic syndrome and 
diabetes compared to no treatment control.  
Conclusions 
Lifestyle interventions demonstrated significant improvement in weight, reduction in hypertension and reduction in 
risk of type 2 diabetes and the metabolic syndrome.   
Word count: 213. 
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2. Introduction  
Obesity and related disease present a public health crisis. Energy-dense diets and sedentary lifestyles are associated 
with obesity. Changing behaviours to reduce disease burden is recognised on a European and global scale through 
the EU Platform for Action on Diet, Physical Activity and Health1 and the WHO global strategy on diet, physical 
activity and health2.  The UK government obesity strategy and £75m campaign3 is in response to the NICE obesity 
guidance4 and future predictions in the Foresight report5.  Through the Change4Life campaign3 the UK Department 
of Health is providing £30m to help nine towns encourage healthy lifestyles6.  
These initiatives are underpinned by evidence from interventions which focus on changing behaviours. An earlier 
review7 of obesity treatments recommended that a systematic review of interventions to prevent obesity should be 
undertaken. 
This systematic review is the first phase of the National Prevention Research Initiative funded economic evaluation 
of obesity prevention for UK adults. The objective is to determine the effectiveness of interventions that focus on 
improving diet and activity behaviours in adults who are normal weight, overweight and obese, to prevent weight 
gain and morbidity in the long-term.  
 
3. Methods 
Included were randomised controlled trials (RCTs) and controlled before and after studies (CBAs) of a lifestyle 
interventions (diet, exercise, behaviour, environmental) in adults (18-65y) with body mass index (BMI) <35kg /m
2
 
reporting weight at least two years post randomisation.  Data were also extracted for risk factors, morbidity and 
mortality. The amount and distribution of fat determines the risk of obesity-related diseases and in general the more 
overweight the greater the risk. Adults classified as pre-obese (BMI 25.0-29.9 kg /m
2
) or obese class 1 (BMI 30.0-
34.9 kg /m
2
) are an important target group for the prevention of weight gain because they have an increased risk of 
elevated risk factors for disease and obesity-related morbidities; such as dyslipidaemia, hypertension, impaired 
glucose tolerance, metabolic and hormonal changes, which in turn contribute to cardiovascular disease, cancers, 
metabolic and endocrine diseases such as type 2 diabetes, and osteoarthritis.  
Diets categorization included: 600kcal/day deficit/low-fat diet; low-calorie diet (LCD) (1000-1600 kcal/d); very 
low-calorie diet (VLCD) (<1000 kcal/d). Interventions were categorised as interventions with definite intention to 
lose weight (clearly targeted calorie reduction) and interventions with no definite intention to lose weight (no target 
for weight loss).  No type of diet was excluded. If an intervention included two or more diets, the most stringent 
calorie restriction was used to classify the diet. 
For exercise or behaviour therapy interventions study investigators had to give a detailed description of the 
components of the intervention and details of the theory underpinning the behavioural intervention.   
Interventions targeting smoking cessation or salt reduction in addition to weight loss were not included. Studies 
were excluded in participants with eating disorders, pregnant women and severely mentally or physically 
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handicapped adults. Studies in non-white populations were included if the ethnic group and setting were relevant to 
the UK ethnic population. 
The literature search involved four phases (see Appendix 1 for search strategies). Phase one: primary studies 
identified from two systematic reviews4;7.  Phase two: CAB Abstracts, CDSR, CINAHL, DARE, EMBASE, 
MEDLINE and PsycINFO were searched and systematic reviews were screened for primary studies. Phase three: 
CAB Abstracts, CCTR, CINAHL, EMBASE, MEDLINE and PsycINFO were searched for primary studies 
published between January 2005 - August 2006.  Phase four: MEDLINE was searched for primary studies 
published between September 2006 - August 2007.  A search of one database only was carried out in the final 
phase in order to identify any studies published since the main searches were performed in August 2006. No 
language restriction was applied. Only full reports from 1990 were considered.  The International Journal of 
Obesity (January 2006 - August 2007) and Obesity were hand-searched online from January 2006 - September 
2007 in order to identify studies which were not yet indexed on electronic databases. 
Where results from studies could be quantitatively combined meta-analyses were undertaken.  Data from RCTs and 
CBAs were analysed separately. Data synthesis (including handling of missing data) and quality assessment were 
based on those previously undertaken7.  For continuous data a weighted mean difference (WMD) was calculated 
(weighted by the inverse of the variance of the effect estimate) and Mantel-Haenszel methods were applied for 
dichotomous data; both using a fixed effects approach and RevMan 4.2.5 software8. In the case of missing standard 
deviations (SDs) for changes in weight and risk factors, assumptions were made (irrespective of whether the 
changes were negative or positive). A linear regression was made of the SD of the mean change in weight on the 
absolute mean change for weight, for the studies which provided these data, and used to impute values for missing 
SDs: 
● SD of weight change in kg = 5.915 + (0.283 x mean change in weight). 
Similar linear regressions were attempted for risk factors. However, clear relationships were not found, so the 
means of reported SDs were used to impute values for missing SDs (see Appendix 14): 
● SD for change in SBP = 12.7 mmHg 
●SD for change in DBP = 8.3 mmHg 
●SD for change in cholesterol = 1.08 mmol/l 
●SD for change in LDL cholesterol = 0.74 mmol/l 
●SD for change in HDL cholesterol = 0.29 mmol/l 
●SD for change in triglycerides = 0.96 mmol/l. 
In the case of fasting plasma glucose and HbA1c, two levels of SDs were used, to allow for the greater variability 
of such measures evident from the studies. 
● If the initial fasting plasma glucose was <7 mmol/l, the SD for change in fasting plasma glucose was 1.35 
mmol/l. 
● If the initial fasting plasma glucose was ≥ 7 mmol/l, the SD for change in fasting plasma glucose was 3.77 
mmol/l. 
● If the initial HbA1c was < 7%, the SD for change in HbA1c was 0.71%. 
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● If the initial HbA1c was ≥ 7%, the SD for change in HbA1c was 2.58%. 
 
Results were described separately for individual studies where the change in outcome data between two time-points 
could not be calculated or the number of participants in each group was not reported. 
 
4. Results  
4.1 Literature search 
Thirty-nine RCTs9-62;64 and one CBA63were included (Figure1, Table 1). Twenty-four studies were US-based, four 
were based in Finland, three in The Netherlands, two in the UK27;28, two in Canada, two in India, and one each in 
Germany, Italy and Australia. Eight were community studies and 32 were in secondary care. Twenty studies were 
24-months in duration, 11 studies were between 30 and 36-months duration and nine studies ranged in duration 
from 38 to 97 months.  Twenty studies recruited 200-2000 participants and five studies recruited over 2000 
participants. In studies with less than 200 participants; sample size ranged from 16 to 180. The largest study was 
the Women’s Health Initiative Dietary Modification Trial42;45;46;61;62 (WHIDMT) with nearly 49,000 women. 
Twenty-five studies recruited men and women, 14 studies recruited women and one study recruited men. At least 
29 studies recruited participants with risk factors for disease, history of disease or disease, such as hypertension, 
type 2 diabetes and breast cancer. Mean baseline BMI was <30kg/m
2
 in 22 studies, unclear in two studies and 
≥30kg/m
2
 in 16 studies. The majority of studies had a mean age between 40-60 years.  
Twenty-four studies specifically intended participants to lose weight and 16 did not. Thirty-two studies included 
two comparisons groups only (Table 2). Forty studies provided 39 different comparisons. There were no long-term 
studies identified that compared an exercise intervention to control.  
Reports of the 39 RCTs9-62;64 varied in quality with 12 clearly reporting allocation concealment, 10 applying an 
intention-to-treat analysis and two reporting effective blinding of outcome assessors (Table 3).   
 
4.2 Study results (Table 4) 
Studies with an intention to lose weight 
Dietary interventions versus control 
600 kcal/day deficit/low-fat diet versus control 
Five studies assessed a 600 kcal/day deficit/low-fat diet21;22;24;30;33-34. Three studies recruited people with 
hypertension or ‘high normal’ blood pressure, one study recruited patients with oesophageal cancer and one 
recruited participants with impaired glucose tolerance (IGT). 
 
Weight  
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600 kcal/d deficit or low-fat diet was associated with non-significant weight changes at 24 and 30 months. 
However at 36 months, the Hypertension Prevention Trial22 (HPT) was associated with a significant WMD weight 
change of -3.49 kg (95% confidence interval (CI) -4.63 to -2.35 kg).  
Two studies were not included in the meta-analyses. Kristal et al24 reported a non-significant intervention effect on 
weight compared with control at 36 months (-1.4 kg). Ramachandran et al30 reported a significant increase in 
weight from baseline at 24 and 30 months in the control group (approximately 0.8 and 0.95 kg respectively) and at 
24 months only in the diet group (approximately 0.4 kg). 
 
Risk factors 
In the HPT22, blood pressure improved with diet at 36 months but did not reach statistical significance. 
 
Clinical outcomes  
Participants receiving diet in the Hypertension Optimal Treatment21 (HOT) study required significantly fewer 
antihypertensive medications. Nine percent of intervention and control groups required drug treatment for 
hypertension during the three years of the HPT22. Weight loss increased the likelihood a patient would be 
controlled on antihypertensive monotherapy in the Trial of Antihypertensive Interventions and Management 
(TAIM) study33-35. 
In Ramachandran et al30 the cumulative incidence of diabetes at three years was 55% in the control group and 
39.3% in the diet group. Relative risk reduction was 28.5% compared with control.  
 
Low-calorie diet (LCD) versus control 
Weight  
One study38 was associated with a significant WMD weight change of -7.00 kg (95% CI -10.99 to -3.01 kg) at 24 
months and -6.10 kg (95% CI -10.71 to -1.49 kg) at 36 months in 54 women treated for breast cancer. Wide CIs 
reflect the small sample size and there was nearly 40% dropout at 36 months. 
 
Weight Watchers versus self-help 
Weight 
One study20 of Weight Watchers was associated with a significant WMD weight change of -2.70 kg (95% CI -3.95 
to -1.45 kg) at 24 months (423 adults, majority women, BMI 34 kg/m2).  
 
Risk factors 
Authors reported no significant difference between groups for risk factors or quality of life at 24 months. 
 
600 kcal/day deficit/low-fat diet plus meal replacements versus control 
Weight  
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One study63 of a 600 kcal/day deficit/low-fat diet using meal replacements (Slimfast shakes twice daily for three 
months then once daily for 57 months) compared with a no-contact matched control group was associated with a 
WMD weight change of -11.49 kg (95% CI -12.98 to -10.00 kg) at two years.  
 
Very low calorie diet (VLCD) using meal replacements (Cambridge diet) versus low-fat control 
Weight  
There was a non-significant weight change in favour of VLCD at 24 months amongst 16 obese Finnish adults with 
newly diagnosed type 2 diabetes31. Risk factor data were not assessed as there were significant baseline differences 
between groups. 
 
Behavioural interventions versus control 
Weight  
Behaviour therapy delivered either by telephone or mail by trained nutritionists versus control showed no 
significant effect on weight at 24 months in US adults from a managed care organisation54. Cost-effectiveness of 
telephone counselling was $132/kg lost, with mail and usual care control achieving similar cost-efficiency of $72/ 
kg lost. 
 
Diet and exercise versus control 
Three RCTs18;19;26;28;59 assessed diet and exercise and all participants were at high risk of or had IGT. The types of 
diet and exercise interventions varied between studies (Table 1). 
 
Weight 
Diet and exercise was associated with significant WMD weight change at 24 months (-2.56 kg, 95% CI -3.34 to -
1.77 kg).  
 
Risk factors 
There was an associated improvement in triglycerides in two studies26;28 (WMD -0.54 mmol/L, 95% CI -0.85 to -
0.24 mmol/L) and fasting plasma glucose (FPG) in three studies18;19;26;28;59 (WMD -0.30 mmol/L, 95% CI -0.42 to -
0.18 mmol/L) but not cholesterol, blood pressure or HbA1c.  
 
Clinical outcomes  
At four years the cumulative incidence of diabetes in the Finnish Diabetes Prevention Study (FDPS) was 11% 
(95% CI 6 to 15%) in the intervention group and 23% (95% CI 17 to 29%) in the control group (risk of diabetes 
reduced by 58%).  At six years there was a 43% reduction in relative risk (RR)18;19. Normal glucose tolerance was 
present in 50% of intervention participants and 29% of control participants after two years in the study by Mensink 
et al26 (P<0.05). In the FDPS, at mean follow-up 3.9 years; 62.6% intervention participants and 71.2% control 
participants had metabolic syndrome (sex and age-adjusted odds ratio (OR) 0.62 (95% CI 0.40 to 0.95)59. 
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Diet, exercise and behaviour therapy versus control 
Five RCTs16;17;23;25;27;36;37 assessed diet, exercise and behaviour therapy. The types of diet and exercise interventions 
varied between studies (Table 1). 
 
Weight  
Diet and exercise and behaviour therapy was associated with significant WMD weight changes at 24 months (-2.47 
kg, 95% CI -3.18 to -1.77 kg, two studies), 30 months (-2.04 kg, 95% CI -2.70 to -1.39 kg, two studies) and 54 
months (-2.50 kg, 95% CI -3.59 to -1.41 kg, one study).  
We were unable to meta-analyse the Diabetes Prevention Program16;17 (DPP) however the authors reported average 
weight loss at 2.8 years was 5.6 kg in the intensive low-fat diet, exercise and behavioural modification programme 
and 0.1 kg in the control group.  Kuller et al25 did not present participant numbers for the 30 and 42-month follow-
up however the authors reported significant improvement in weight. 
 
Risk factors  
The benefit of significant weight loss was not consistently reflected in improved risk factors. Although Kuller et 
al25 demonstrated significant weight loss and improvements in LDL-cholesterol there was no significant 
improvement in HDL-cholesterol, triglycerides, FPG or blood pressure at 54 months. The Trials of Hypertension 
Prevention phase II36;37 (TOHPII) study demonstrated significant weight loss and showed significant improvement 
in systolic but not diastolic blood pressure at 30 months. 
 
Clinical outcomes 
The DPP16;17 significantly reduced the risk of developing diabetes and the metabolic syndrome for up to three years 
in over 2000 obese adults with IGT at baseline. 
In the DPP16;17 the crude incidence of diabetes was 11/100 in the control group and 4.8/100 in the lifestyle 
intervention. The incidence of diabetes was 58% lower (95% CI 48 to 66%) in the lifestyle intervention group than 
the control. The estimated cumulative incidence of diabetes at three years was 28.9% in the control and 14.4% in 
the lifestyle-intervention group. Incidence of metabolic syndrome was reduced 41% in the lifestyle intervention 
compared with control (P<0.001).   
In TOHP II36;37, the RR of developing hypertension for the weight loss group was 0.87 (p=0.06) at 48 months. 
 
Adjuncts to diet 
The addition of extra fruit and vegetables and exercise to a low-fat low-cholesterol diet was associated with a 
weight change of -6.10 kg compared with -2.1 kg in the low-fat low-cholesterol group at 36 months in mostly men 
with or at risk of coronary artery disease32. Authors reported significant improvement in cholesterol, triglycerides, 
fasting blood glucose and blood pressure.  
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The addition of exercise and behaviour therapy to diet was associated with a non-significant difference in weight 
loss between groups at 24 months in one study of obese adults with type 2 diabetes10. A significant improvement in 
total cholesterol was found at 24-months (-0.3 mmol/L (95% CI -0.6 to -0.1 mmol/L) but not for blood pressure. 
The addition of meal replacements (Slimfast) to a low-fat diet for the initial three months was associated with a 
non-significant weight change at 27 months but a significant weight change at 51 months (-5.40 kg, 95% CI -8.97 
to -1.83 kg) 14;15;43. There was significant improvement in HDL-cholesterol at 27 months (0.17 mmol/L, 95% CI 
0.03 to 0.31 mmol/L) and SBP at 51 months (-12.0 mmHg, 95% CI -17.75 to -6.25 mmHg) but not other risk 
factors. 
Women who received meal replacements (Slimfast) as part of low-fat diet, exercise and behaviour therapy provided 
in group sessions by a dietitian maintained the greatest weight loss at two years (WMD weight change -6.00 kg 
(95% CI -10.19 to -1.81 kg)9. However dropout was 65% at 24 months. The addition of meal replacements was 
associated with significant improvement in HDL-cholesterol (0.01 mmol/L, 95% CI 0.00 to 0.02 mmol/L) and 
glucose at 24 months (0.03 mmol/L, 95% CI 0.00 to 0.05 mmol/L) but not other risk factors. 
The addition of pre-packaged food provision or financial incentives, or both combined and compared with a low-
calorie diet, exercise and behaviour therapy intervention, did not significantly improve weight loss at 30 months in 
200 overweight US adults in their late 30s23. 
 
Head-to-head comparisons 
One study of higher energy expenditure (2500 kcal/wk) through exercise and increased social support plus small 
monetary incentives, compared with 1000 kcals/wk was associated with a non-significant weight change at 30 
months55. Both groups received low-fat diet and standard behaviour therapy. 
There was no significant difference in weight between delivering behaviour therapy by telephone compared with 
mail in 1801 obese US adults from a managed care organisation at 24 months54. 
There was no significant difference in weight at 24 months between women who were seen by a dietitian in a group 
and women seen by a nurse or physician in a clinic.  Both groups received low-fat diet including meal 
replacements, exercise and behaviour therapy9. 
Glucose (0.03 mmol/L, 95% CI 0.01 to 0.05 mmol/L) and LDL-Cholesterol (0.02 mmol/L, 95% CI 0.01 to 0.03 
mmol/L) were significantly improved in the nurse/physician group compared with the dietitian group at 24 months. 
There was significant difference in favour of lowered SBP for the dietitian group (-17.00 mmHg, 95% CI -27.91 to 
-6.09 mmHg). No other risk factor data was significantly different9. 
4.3 Studies where the primary intention was not to lose weight 
Dietary interventions versus control 
Weight 
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A low-fat non-reducing diet was associated with a statistically significant weight change of -1.42 kg (95% CI -2.10 
to -0.74 kg) at 24 months from two studies13;39; 40.  Both studies were in women of normal weight who had either 
survived breast cancer or were at risk of breast cancer.   
Two other studies reported weight change. There was a significant reduction in weight in the intervention group 
compared with the control at 24-months (approximately -1.6 kg vs +1.5 kg respectively) in the feasibility trial for 
the Women’s Intervention Nutrition Study41 (WINS-FT). In another study the intensive diet group increased mean 
weight by 2.09 kg and the routine diet group increased weight by 1.57 kg at a median of 51 months follow-up57. 
There was a significant difference in the follow-up duration (median 58.6 months for intensive diet and 47.9 
months for routine diet).  
 
Clinical outcomes 
There was no significant difference in the incidence of diabetes at 51 months in women of normal weight with a 
recent history of gestational diabetes57, 6.1% for the intensive diet group and 7.3% for the routine diet group, an 
incidence rate of 0.83 (95% CI 0.47 to 1.48, p=0.50).  
A low-fat non-reducing diet significantly reduced the area of mammographic density (a risk factor for cancer) 
compared with control at two years13.  
 
Behavioural interventions versus control 
Weight 
Behaviour therapy versus control showed no significant effect on weight at 24 months (one study of 115 physically 
active Canadian undergraduates, mean age 20y, mean BMI 22.4 kg/m2)50.  
 
Risk factors 
There were no significant differences between groups in total cholesterol or HDL-cholesterol, however there was a 
significant difference in favour of behaviour therapy for triglycerides at 24 months (-0.20 mmol/L, 95% CI -0.40 to 
0.00 mmol/L)50. 
 
Diet and exercise versus control 
Weight 
Diet and exercise education – with or without financial incentives - did not prevent weight gain in 809 overweight 
but otherwise healthy adults in one community-based study (Pound of Prevention) at 24 and 36 months29. For diet 
and exercise, diet and exercise with incentives, and control; weight change was +1.3 kg, +1.2 kg, +1.4 kg at two 
years and +1.6 kg, +1.5 kg, +1.8 kg at three years respectively. 
 
Diet and behaviour versus control 
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Four studies42;45;46;52;58;60-62;64 ranged in size from 2079 participants to 48835 women. The Polyp Prevention Trial52;60 
(PPT) recruited men and women with a recent large-bowel adenomatous polyp, two studies; Women’s Healthy 
Eating and Living58 (WHEL) and Women’s Intervention Nutrition Study64(WINS) recruited women with 
previously treated or resected early stage breast cancer, and the Women’s Health Initiative Dietary Modification 
Trial42;45;46;61;62(WHIDMT) recruited postmenopausal women. 
 
Weight 
Diet and behaviour therapy was associated with a significant weight change of -1.01 kg (95% CI -1.34 to -0.68 kg, 
2 studies) at 24 months, -1.77 kg (95% CI -1.94 to -1.59 kg, 3 studies) at 36 months (figure 2), -0.52 kg (95% CI -
0.85 to -0.19 kg, 2 studies) at 48 months and -0.70 kg (95% CI -0.90 to -0.50 kg, one study) at 90 months. The 
difference in weight was not significant at 72 months. There was significant heterogeneity between the studies.  
WINS64 reported a difference between intervention and control (in favour of intervention) of -1.8 kg (95% CI -3.1 
to 0.2 kg) at three years and -2.7 kg (95% CI -4.5 to -0.9 kg) at five years. 
 
Risk factors 
Despite significant weight loss, the PPT52;60 showed no significant difference between groups for cholesterol at 24, 
36 and 48 months.  
 
Clinical outcomes 
Diet and behaviour therapy interventions did not significantly reduce incident cancers including colorectal, breast, 
endometrial or ovarian cancer61, risk of recurrent adenomatas60 or mortality from colorectal or breast cancer45;46 
over 8 years.  However interim results suggest that intervention women in WINS64 had a 24% lower risk of relapse 
events than women in control at five years (HR 0.76, 95% CI 0.60, 0.98).  
The WHIDMT showed no significant difference in overall incidence of ovarian cancer (hazard ratio (HR) 0.83, 
95% CI 0.60 to 1.14) and cancer of the endometrium (HR 1.11, 95% CI 0.88 to 1.40) at 8.1 years. However ovarian 
cancer risk was lower in the intervention group for the final four years (HR 0.60, 95% CI 0.38 to 0.96) 61. HR for 
colorectal cancer was 1.08 (95% CI 0.90 to 1.29) and mortality from colorectal cancer was 1.26 (95% CI 0.85 to 
1.85) over 8.1 years 45;46. HR for breast cancer was 0.91 (95% CI 0.83 to 1.01)  and mortality from breast cancer 
was 0.77 (95% CI 0.48 to 1.22)45;46.  HR for confirmed breast cancer event was 0.96 (95% CI 0.80 to 1.14; P = 
0.63) in the WHEL58study over 7.3 years. 
Risk of recurrent adenomatas was not significantly reduced in intervention participants of the PPT at four or eight 
years (RR 0.98, 95% CI 0.81 to 1.39 at 8y)60.  
The WHIDMT found no evidence for reducing diabetes risk after 8.1 years, HR 0.96 (95% CI 0.90 to 1.03)62. 
 
Diet, exercise and behaviour therapy versus control 
Weight 
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Diet and exercise and behaviour therapy (clinic-based or home-based) was associated with non-significant weight 
changes at 24 and at 36 months compared with control in 284 healthy women in their mid 30s53.  
 
Adjuncts to diet 
Diet plus exercise versus diet 
Two RCTs set in Finland were included11;12;49. One study was community-based and recruited 90 men at risk of 
developing the metabolic syndrome (BMI 30-40 kg/m2, waist circumference >100cm) 11;12. The other49 recruited 
eighty-two women, mean age 40 years, mean BMI 34 kg/m2. Both included studies had a VLCD of 8-12 weeks and 
had a mean weight loss of 13.1 to 14.3 kg prior to randomisation.  
 
 
Weight 
The addition of exercise to a low-fat diet was associated with a non-significant weight change at 29-33 months, 
irrespective of type (walking or resistance training) or amount (3.6 MJ/wk-8.4 MJ/wk) (figure 3). Men randomised 
to the walking group had 33% dropout compared with 13% dropout in the resistance training group11;12. 
 
Risk factors 
The addition of exercise to a low-fat diet did not improve risk factors in women at 33 months49. 
Clinical outcomes 
The OR for the occurrence of metabolic syndrome (from two months prior to randomisation, both groups 
combined) was 0.29 (95% CI 0.16 to 0.50).11;12.   
 
Other comparisons 
A Mediterranean diet with behaviour therapy versus a standard low-fat diet was associated with significant weight 
change at 24 months (-2.80 kg, 95% CI -3.06 to -2.54 kg) in 180 sedentary Italian adults with metabolic 
syndrome48. There were significant improvements in total cholesterol (-0.23mmol/L, 95% CI -0.26 to -0.20 
mmol/L) and HDL-cholesterol (0.07 mmol/L, 95% CI 0.06 to 0.08 mmol/L ), triglycerides (-0.21 mmol/L, 95% CI 
-0.23 to -0.29 mmol/L), glucose (-0.33 mmol/L, 95% CI -0.37 to -0.29 mmol/L) and blood pressure (SBP -3.00 
mmHg, 95% CI -3.46 to -2.54 mmHg; DBP -2.00 mmHg, 95% CI -2.29 to -1.71 mmHg) at 24 months.  
A low-fat non-reducing vegan diet compared with a low-fat non-reducing diet was associated with a non-
significant weight change at 24 months in 62 overweight postmenopausal women56. Participants offered group 
support for one year after the initial intervention (regardless of group) lost more weight at 24 months compared 
with participants not offered group support. Vegan supported participants lost significantly more weight than 
unsupported vegan participants at 24 months (-4.95 kg; 95% CI -7.50 to -2.40 kg) (figure 4). 
There was no significant difference in weight between clinic-based diet, exercise and behaviour therapy and home-
based diet, exercise and behaviour therapy at 24 and 36 months in 284 healthy normal weight women in their mid 
30s53. 
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There was no significant difference in BMI between supervised group-based higher-intensity exercise set in the 
community versus unsupervised individual higher-intensity home-based exercise51. There was no significant 
difference in BMI between unsupervised individual higher-intensity home-based exercise and unsupervised 
individual lower-intensity home-based exercise51.  There were no significant differences between groups for risk 
factors. 
There was no significant difference in weight between traditional structured exercise and behaviour therapy versus 
lifestyle physical activity and behaviour therapy at 24 months in 237 sedentary, overweight adults47. Only 
triglycerides were significantly improved in participants in the traditional structured exercise group compared with 
lifestyle physical activity at 24 months (-0.18 mmol/L, 95% CI -0.33 to -0.03 mmol/L).  
There was no significant difference in weight or risk factors between exercise to expend 8.4 MJ/wk versus 4.2 
MJ/wk (both groups received diet) at 33 months in 82 obese premenopausal women49. 
There was no significant difference in weight between walking (5.2 MJ/wk) and resistance training (3.6 MJ/wk) at 
31 months in 90 obese men11;12. 
Low-fat non-reducing diet and exercise with incentives compared with low-fat non-reducing diet and exercise 
without incentives did not prevent weight gain in 809 overweight but otherwise healthy adults in one community-
based study at 24 and 36 months29. Diet with exercise and incentives versus diet with exercise; weight change was 
+1.2 kg vs. +1.3 kg at two years and +1.5 kg vs. +1.6 kg at three years. 
 
4.4 Deaths and clinical outcomes  
Meta-analyses showed no significant difference between lifestyle interventions and control groups for deaths 
(figure 5), stroke, heart disease or cancer outcomes.  Diet and behaviour therapy suggest reduced risk of breast 
cancer recurrence at five years64 and ovarian cancer in the final four years of an eight year trial61. 
Interim results suggest that intervention women in WINS64 had a 24% lower risk of breast cancer recurrence than 
women in control at five years (HR 0.76, 95% CI 0.60 to 0.98). Ovarian cancer risk was lower in the intervention 
group for the final four years (HR 0.60, 95% CI 0.38 to 0.96) of the WHIDMT 61. 
There is evidence that lifestyle intervention can prevent diabetes and the metabolic syndrome. Two studies were 
terminated early16;17;30 due to unequivocal evidence of effectiveness of the lifestyle intervention in significantly 
reducing the risk of developing type 2 diabetes. 
The DPP16;17 demonstrated that an intensive low-fat diet, exercise and psychological support intervention compared 
with control can prevent the metabolic syndrome at three years (OR 0.54, 95% CI 0.42 to 0.69). Combined data 
from the DPP16;17  and a study of Mediterranean diet and behaviour therapy versus standard low-fat diet48 showed 
that these interventions can resolve cases of the metabolic syndrome for up to three years (RR 2.52, 95% CI 2.08 to 
3.05). (In this case an RR of greater than 1 favours treatment as higher resolutions indicates a better outcome). In 
the FDPS59, at mean follow-up 3.9 years; 62.6% intervention participants and 71.2% control participants had 
metabolic syndrome (sex and age-adjusted OR 0.62 (95% CI 0.40-0.95). 
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Three studies18;19;27;30;59 (diet versus control; diet and exercise versus control; diet, exercise and behaviour therapy 
versus control) showed a significant effect on the prevention of type 2 diabetes up to 6 years (RR 0.68, 95% CI 
0.57 to 0.82). This result is consistent with the results from the DPP16;17 in which the incidence of diabetes was 58% 
lower (95% CI 48 to 66%) in the intensive lifestyle intervention group than the control. However the WHIDMT62 
showed no evidence of reducing diabetes risk after 8.1 years. 
 
5. Discussion  
This systematic review captured a relatively large number of studies (40), capturing interventions aimed at 
preventing weight gain in adults who were normal weight, overweight and obese. In doing so it extends the 
evidence base beyond a recent review65.  
Eleven of 39 comparisons produced significant improvement in weight, of which eight compared an intervention to a 
non-treatment control. Eight intended to produce weight loss and produced greater weight loss than the three studies 
not intending weight loss (WMD weight change 2.0-11.5 kg versus 0.5-2.8 kg respectively). 600kcal/day deficit/low-
fat diets with and without meal-replacements, low-calorie diets, Weight-Watchers, low-fat non-reducing diets; diets 
with behaviour therapy, exercise or exercise and behaviour therapy produced significant improvement in weight 
compared with control. Weight loss ranged from -0.5 kg to -11.5 kg. Adding meal replacements produced significant 
improvement in weight particularly long-term. Direct comparisons of interventions failed to show significant effect 
on weight with the exception Mediterranean diet and behaviour therapy compared with a low-fat diet.  
Interventions combining diet with additional elements compared to control were not always associated with greater 
weight loss. Both diet and exercise and diet, exercise and behaviour therapy produced similar weight changes, less 
than some of the diets alone and similar to that achieved by Weight Watchers20. There was insufficient evidence to 
assess the benefit of adding exercise or behaviour therapy. There were no studies that assessed the effectiveness of 
adding behaviour therapy or exercise and behaviour therapy to a non-reducing diet. There did not appear to be any 
obvious pattern between intensity of contact or diet prescription and weight change.  
The four meal replacement studies9;14;15;31;43;63 began with an intensive phase consisting of meal replacements 2-3 
times daily for three months, then three studies continued to use meal replacements less often (in one study both 
groups received meal replacements for the maintenance period). Significant benefit to weight was demonstrated in 
the two studies that assessed the addition of meal replacements in the maintenance phase, although one of these 
was not a randomised study63.  
Risk factor data were limited; weight loss did not consistently improve risk factors, some risk factors improved 
independent of weight change. Another review including lifestyle interventions of at least two years duration found 
that weight loss of at least 5% baseline weight was not consistently associated with improvement in cardiovascular 
risk factors and benefits were specific to the intervention and occurred mainly in people with cardiovascular risk 
factors66.  
Few studies were powered to detect differences in morbidity and mortality or followed up for sufficient time. There 
was no significant difference between lifestyle interventions and control groups for deaths, stroke, heart disease or 
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cancer. Diet and behaviour therapy suggest reduced risk of breast cancer recurrence at five years64 and ovarian 
cancer in the final four years of an eight year trial61. 600 kcal/day deficit/low-fat diets can reduce type 2 diabetes, 
improve blood pressure and reduce antihypertensive medication for up to three years. Diet and exercise reduce the 
risk of type 2 diabetes for up to six years and the metabolic syndrome at four years, compared to control. Diet with 
exercise and behaviour therapy can reduce the risk of type 2 diabetes, hypertension and the metabolic syndrome. 
The addition of exercise to diet can reduce the risk of metabolic syndrome in men. However a non-reducing diet 
and behaviour therapy did not reduce diabetes risk in nearly 49,000 women after 8.1 years62. 
Research is required into whether effectiveness of interventions varies with baseline risk, age, gender, ethnic group 
and setting. WHIDMT62 suggests that relatively small amounts of weight loss without increase in physical activity, 
may account for why the intervention did not reduce the risk of diabetes compared with the FDPS18;19;59 and 
DPP16;17;44. Participants in the FDPS and DPP were at higher risk of developing diabetes and had higher baseline 
BMI compared to the WHIDMT. In the DPP44, lifestyle intervention was most effective in preventing diabetes in 
older participants (60-85y) perhaps due to greater weight loss and physical activity. Interim analysis of WINS64 diet 
and behaviour intervention suggests significantly reduced risk of breast cancer recurrence in postmenopausal 
women, whereas the WHIDMT42;45;46;61;62 and WHEL58 studies did not significantly reduce breast cancer morbidity. 
Women in the dietary intervention arm of WINS lost more weight than the other studies which may account for the 
lowered risk. 
There was scant reporting of economic or quality of life data. The FDPS was used to assess whether a lifestyle 
intervention to prevent diabetes in adults with IGT is cost-effective in a Swedish setting67. The model predicted that 
the intervention would be cost-saving, with an increase in estimated survival of 0.18 years. The predicted cost-
effectiveness ratio was €2,363 per quality-adjusted life-year gained.  
It was difficult to determine whether some studies were supposed to affect weight or not, or whether exercise or 
behaviour therapy were provided, and to classify types of diet. Classification of interventions was difficult because 
the information reported within the papers was insufficient; classification was often arrived at by a consensus 
process between reviewers. Where the calorie content of a diet was not clearly stated it was categorized as a ‘600 
kcal/day deficit or low-fat diet’ (where there was a definite intention to provide weight loss) or ‘low-fat non-
reducing diet’ (where there was no definite intention to provide weight loss). For exercise or behaviour therapy 
interventions to be categorised as such, study investigators had to give a detailed description of the components of 
the intervention.   
Studies were heterogeneous and the varied comparisons were underpinned by few studies making it difficult to 
generalise about effective interventions.  There were inadequate data reported to include some studies in meta-
analyses, in addition, it was necessary to calculate weight and risk factor change from absolute values or from 
graphs which meant that standard deviations needed imputing in 25% of studies.  A minority of studies reported 
adequate allocation concealment, intention-to-treat analyses or blinding of outcome assessors. It was not possible to 
assess the differential effects of interventions according to demographic, socio-economic or cultural 
characteristics68.  
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There is limited evidence for lifestyle interventions to prevent weight gain in healthy normal weight adults within 
the community. To widen the evidence-base requires review of uncontrolled interventions and synthesis of 
evidence from complex public health interventions with new methods to assess evidence. 
These gaps in the evidence base and inadequacies relating to study design and reporting necessitate 
recommendations for future interventions to be longer-term and sufficiently powered to detect clinical outcomes. 
Adequate reporting of outcome data would enable all studies to be included in meta-analyses (where relevant to do 
so). Detailed reporting of interventions, participant characteristics, economic and quality-of-life data would 
improve the quality of future systematic reviews of lifestyle intervention. 
 
Conclusion 
Diet, alone and with the addition of exercise and/or behaviour therapy demonstrated significant weight loss and 
improvement in metabolic syndrome and diabetes compared to no treatment control for at least two years.  
 
Word count: 5848.  
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APPENDIX 1. Search strategies. 
 
FIGURES. 
 
FIGURE 1. Flow diagram for locating primary studies of controlled trials for systematic review. 
 
FIGURE 2. Diet and behaviour therapy versus control at 36 months. No intention to lose weight. 
 
FIGURE 3. Diet and exercise versus diet at 29/33 months. No intention to lose weight. 
 
FIGURE 4. Low-fat vegan diet versus low-fat NCEP diet at 24-months. No intention to lose weight. 
 
FIGURE 5. Overall deaths.    
      
TABLES. 
 
TABLE 1  Table of included studies. 
 
TABLE 2   Overview of included studies. 
 
TABLE 3  Table of quality assessment of RCTs. 
 
TABLE 4  Table of weight results from meta-analyses. 
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APPENDIX 1 Search strategies. 
 
A. Search strategy to identify systematic reviews in MEDLINE and EMBASE and adapted for other 
databases. 
1. Obesity/ 
2. Overweight/ 
3. weight gain/ 
4. weight loss/ 
5. obesity.ti,ab. 
6. obese.ti,ab. 
7. (los$ adj1 weight).ti,ab. 
8. (gain$ adj1 weight).ti,ab. 
9. (overweight or over weight or over-weight).ti,ab. 
10. (change$ adj1 weight).ti,ab. 
11. (weight adj1 maint$).ti,ab. 
12. (weight adj1 reduc$).ti,ab. 
13. (weight adj1 control).ti,ab. 
14. ((bmi or body mass index) adj2 (gain or loss or change)).ti,ab. 
15. ((bmi or body mass index) adj2 (maint$ or reduc$)).ti,ab. 
16. (prevent$ adj1 (weight gain or obesity)).ti,ab. 
17. or/1-16 
18. exp meta analysis/ 
19. metaanalys:.ti,ab. 
20. meta-analys:.ti,ab. 
21. meta analys:.ti,ab. 
22. cochrane.ti,ab,sh. 
23. (synthes: adj3 (quantitative: or literature: or research or studies or data)).ti,ab. 
24. pooled analys:.ti,ab. 
25. ((data adj2 pool:) and studies).ti,ab. 
26. ((review: or overview:) adj10 (systematic: or methodologic: or quantitativ: or research: or literature: or studies: 
or trial: or effective:)).ti,ab. 
27. or/18-26 
28. (retrospective: adj2 review:).ti,ab,sh. 
29. (case: adj2 review:).ti,ab,sh. 
30. (patient: adj 2 review:).ti,ab,sh. 
31. (patient: adj2 chart:).ti,ab,sh. 
32. (peer: adj2 review:).ti,ab,sh. 
33. (chart: adj2 review:).ti,ab,sh. 
34. (case: adj2 report:).ti,ab,sh. 
35. or/28-34 
36. 35 not (35 and 27) 
37. 27 not 36 
38. editorial.pt. 
39. letter.pt. 
40. or/38-39 
41. 37 not 40 
42. exp animal/ 
43. exp human/ 
44. 42 not (42 and 43) 
45. 41 not 44 
46. 17 and 45 
47. limit 46 to (adolescent <13 to 17 years> or aged <65+ years> or child or embryo or infant or preschool child <1 
to 6 years> or school child <7 to 12 years>) 
48. 46 not 47 
49. limit 48 to yr="1990 - 2006" 
50. Obesity/ 
51. Overweight/ 
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52. weight gain/ 
53. weight loss/ 
54. obesity.ti,ab. 
55. obese.ti,ab. 
56. (los$ adj1 weight).ti,ab. 
57. (gain$ adj1 weight).ti,ab. 
58. (overweight or over weight or over-weight).ti,ab. 
59. (change$ adj1 weight).ti,ab. 
60. (weight adj1 maint$).ti,ab. 
61. (weight adj1 reduc$).ti,ab. 
62. (weight adj1 control).ti,ab. 
63. ((bmi or body mass index) adj2 (gain or loss or change)).ti,ab. 
64. ((bmi or body mass index) adj2 (maint$ or reduc$)).ti,ab. 
65. (prevent$ adj1 (weight gain or obesity)).ti,ab. 
66. or/50-65 
67. exp meta analysis/ 
68. metaanalys:.ti,ab. 
69. meta-analys:.ti,ab. 
70. meta analys:.ti,ab. 
71. cochrane.ti,ab,sh. 
72. (synthes: adj3 (quantitative: or literature: or research or studies or data)).ti,ab. 
73. pooled analys:.ti,ab. 
74. ((data adj2 pool:) and studies).ti,ab. 
75. ((review: or overview:) adj10 (systematic: or methodologic: or quantitativ: or research: or literature: or studies: 
or trial: or effective:)).ti,ab. 
76. or/67-75 
77. (retrospective: adj2 review:).ti,ab,sh. 
78. (case: adj2 review:).ti,ab,sh. 
79. (patient: adj 2 review:).ti,ab,sh. 
80. (patient: adj2 chart:).ti,ab,sh. 
81. (peer: adj2 review:).ti,ab,sh. 
82. (chart: adj2 review:).ti,ab,sh. 
83. (case: adj2 report:).ti,ab,sh. 
84. or/77-83 
85. 84 not (84 and 76) 
86. 76 not 85 
87. editorial.pt. 
88. letter.pt. 
89. or/87-88 
90. 86 not 89 
91. exp animal/ 
92. exp human/ 
93. 91 not (91 and 92) 
94. 90 not 93 
95. 66 and 94 
96. limit 95 to ("all infant (birth to 23 months)" or "newborn infant (birth to 1 month)" or "infant (1 to 23 months)" 
or "preschool child (2 to 5 years)" or "child (6 to 12 years)" or "adolescent (13 to 18 years)" or "aged (80 and 
over)") 
97. 95 not 96 
98. limit 97 to yr="1990 - 2006" 
99. 49 or 98 
100. remove duplicates from 99 
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B. Search strategy to identify primary studies in MEDLINE and adapted for other databases. 
1. Obesity/ 
2. Overweight/ 
3. weight gain/ 
4. weight loss/ 
5. obesity.ti,ab. 
6. obese.ti,ab. 
7. (los$ adj1 weight).ti,ab. 
8. (gain$ adj1 weight).ti,ab. 
9. (overweight or over weight or over-weight).ti,ab. 
10. (change$ adj1 weight).ti,ab. 
11. (weight adj1 maint$).ti,ab. 
12. (weight adj1 reduc$).ti,ab. 
13. (weight adj1 control).ti,ab. 
14. ((bmi or body mass index) adj2 (gain or loss or change)).ti,ab. 
15. ((bmi or body mass index) adj2 (maint$ or reduc$)).ti,ab. 
16. (prevent$ adj1 (weight gain or obesity)).ti,ab. 
17. or/1-16 
18. randomized controlled trial.pt. 
19. controlled clinical trial.pt. 
20. randomized controlled trials/ 
21. random allocation/ 
22. double blind method/ 
23. single blind method/ 
24. controlled clinical trials/ 
25. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 
26. placebos/ 
27. placebo$.ti,ab. 
28. research design/ 
29. control groups/ 
30. (control$ adj3 before adj2 after adj3 (stud$ or trial$ or design$)).ti,ab. 
31. (matched communities or matched populations).ti,ab. 
32. comparison group$.ti,ab. 
33. matched pairs.ti,ab. 
34. (quasiexperimental or quasi experimental).ti,ab. 
35. nonrandomi?ed.ti,ab. 
36. (control$ adj (group$ or trial$)).ti,ab. 
37. randomi?ed.ti,ab. 
38. intervention studies/ 
39. evaluation studies/ 
40. (pretest or pre test or (posttest or post test)).ti,ab. 
41. or/18-40 
42. 17 and 41 
43. animal/ not human/ 
44. 42 not 43 
45. limit 44 to ("all infant (birth to 23 months)" or "newborn infant (birth to 1 month)" or "infant (1 to 23 months)" 
or "preschool child (2 to 5 years)" or "child (6 to 12 years)" or "aged (80 and over)") 
46. 44 not 45 
47. limit 46 to yr="2005 - 2006" 
48. pregnancy/ 
49. 47 not 48 
50. editorial.pt. 
51. letter.pt. 
52. 50 or 51 
53. 49 not 52 
54. eating disorders/ 
55. 53 not 54 
